CBD for Scan Anxiety: The Primary and Secondary Comparisons Disagreed

A CBD scan-anxiety trial did not meet its primary endpoint, although a secondary comparison favored CBD. Reporting only the positive secondary finding would give an incomplete account of the randomized evidence.

One dose before a cancer-related scan

Fifty women with advanced breast cancer and baseline clinical anxiety were randomized equally to 400 mg oral CBD or placebo. Anxiety was assessed before and two to four hours after administration in the setting of an upcoming tumor-assessment scan.

The primary outcome compared changes in the afraid subscale of a validated mood scale between groups. That is a different calculation from comparing the groups’ final anxiety scores alone.

Change scores did not establish superiority

Mean anxiety change was −19.1 in the CBD group and −15.0 in the placebo group. The between-group primary comparison was not significant, with p = 0.37.

A separate comparison of post-dose anxiety levels favored CBD, with p = 0.02. These findings can coexist because baseline levels and the chosen statistical contrast affect the question being tested. A significant final-score comparison does not retroactively turn the primary change-score endpoint positive.

What the study supports

No grade 3 or 4 toxic effects were reported, but one dose in 50 participants cannot establish long-term safety or exclude uncommon adverse effects. The participants’ cancer stage, prior experiences and concurrent treatments also restrict generalization.

The findings justify further study of an acute anxiety signal rather than an unqualified claim that CBD treats cancer-related anxiety. This was a trial of a defined oral preparation and a defined stressor, not evidence that cannabis products broadly relieve every type of distress.

Related: How study design affects interpretation of CBD outcomes.

Primary research

Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Network Open (2024).

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

A laboratory can identify a drug while relying on outside information to classify its prescription status. A national urine-testing study combined analytical results with medication information supplied by the ordering clinician. Two information streams McClure and colleagues analyzed 231,228 test-result sets from 144,535 patients tested for both opioids and benzodiazepines….

Spread the love

Read Article: How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

How Did a Stress-Management Trial Protocol Handle Medication Changes?

When a study evaluates psychological treatment, medication changes can complicate attribution of improvement. The 2017 Seren@ctif protocol described how investigators planned to address this issue in a trial of adjustment disorder with anxiety. The planned comparison Servant and colleagues proposed three randomized groups receiving computer-based stress management, an equivalent face-to-face…

Spread the love

Read Article: How Did a Stress-Management Trial Protocol Handle Medication Changes?

What Evidence Supports Extending Lipid Rescue to a Different Poison?

A treatment that appears useful for one toxicant raises a separate scientific question when proposed for another. Eisenkraft and Falk’s 2016 review of lipid emulsion and chemical-agent poisoning provides an example of that evidence gap. Several evidence types The authors discussed proposed lipid-scavenging, metabolic, and cardiovascular mechanisms. They reviewed laboratory…

Spread the love

Read Article: What Evidence Supports Extending Lipid Rescue to a Different Poison?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us